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Background: Several polymorphisms in the apolipoprotein C3 (APOC3) gene have been found association with
hypertriglyceridemia(HTG), but the link with coronary heart disease(CHD) risk between ethnicities was still
controversial. Among them, reseachers paid more attentions to the promoter polymorphisms T-455C and C-482T
because both of them located in insulin-responsive element (IRE) and insulin was thought to exert its action by
down-regulating APOC3 gene expression. The aim of this study was to investigate the association of the two
polymorphisms of APOC3 with CHD in a Han population in East China.
Methods: TaqMan SNP Genotyping Assays were carried out to detect the genotypes of APOC3 gene, including
the T-455C and C-482T, in 286 subjects with CHD and 325 controls without CHD. The levels of serum lipid profiles
were also detected by biochemical methods.
Results: There was no difference of genotype frequencies and allele frequencies between the CHD population and
the controls(P > 0.05). Compared with the most common genotype -455TT or -482CC, the variants had neither
significantly increased CHD risk, nor the lipid variables showed any statistically relevant differences in the research
population. The adjusted OR of CHD were 5.67 [0.27-18.74] and 0.75 [0.20-2.73] in carriers of the APOC3 -455C and
-482T variants, respectively(P > 0.05). There was also no significant difference in APOC3 haplotype distribution in
CHD and controls, but there was a strong linkage disequilibrium between T-455C and C-482T with D’ = 0.9293,
0.8881, respectively(P < 0.0001).
Conclusions: Our data did not support a relationship between the two polymorphisms of APOC3 gene and risk of
CHD in the Han population in East China.
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Background
Both the genetic and environmental factors contribute to
the development of coronary heart disease (CHD) which is
becoming the leading cause of death in many countries of
the world including China. The metabolism of circulating
particles such as triglyceride-rich lipoprotein (TRL) was
strongly influenced by their content in apolipoprotein C3
(APOC3), a component that inhibits the hydrolysis of
these paticles by lipoprotein lipase, and APOE-mediated
hepatic uptake of them. By far, data from both clinical
evidence [1,2] and mechanism research results [3,4] sup-
p o r t e dt h er o l eo fA P O C 3i nCHD and artherosclerosis
(AS), suggesting that the APOC3 was a strong indepen-
dent risk factor for CHD.
Different genetic and acquired factors impact serum
APOC3 concentrations. Five polymorphisms have been
found in the APOC3 gene promoter. Among them, two
promoter polymorphisms T-455C and C-482T have been
studied more extensively because they just located on the
insulin-responsive element (IRE) in APOC3 gene. Insulin
exerted its action by down-regulating APOC3 gene
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mutant sequences seemed to reduce the inhibitory effect
of the hormone [5].
Patients with type 2 diabetes mellitus(T2DM) increased
levels of circulating APOC3, and it has been linked to
enhanced b-cell apoptosis [6]. Recently we reported that
the T-455C or C-482T variant on the APOC3 gene pro-
moter contributed to an increased risk of HTG in Chinese
Han health population, however, no relationship between
the two polymorphisms and HTG in T2DM patients was
found [7]. Insulin resistance state in T2DM may mask the
effect of a common APOC3 haplotype on the risk of
HTG. A large body of clinical studies have demonstrated
that increased serum triglyceride concentrations were
positively associated with risk for CHD [2,8,9], and low
APOC3 levels were associated with reduced CHD risk
[10,11]. Although several studies have supported an asso-
ciation between these two polymorphisms and CH#1 [12],
others have failed to confirm the relationship [13,14]. Con-
sidering the complex of CHD and race difference, what
condition is in china? In present study, we investigated the
distribution of the two polymorphisms and the relation-




we selected a total of 611 unrelated adult subjects of both
sexes, 286 unrelated Chinese patients (214 males, 72
females, age 56.30 ± 11.57 years) with significant coronary
stenosis by cardiovascular angiography(according to ste-
noss ≥ 50% at least 1 coronary artery)were recruited from
Department of cardiolog of Changzheng Hospital, Second
Military Medical University of China. 325 controls were
selected via health-screening at the Physical Examination
Centre or CHD-free of heart disease patients at the same
hospital (172 males, 153 females, age 55.79 ± 12.40 years).
All subjects were of Han ethnicity in East China.
The informed consent was obtained from subjects
who agreed to participate in the study, and the study
had the approval of the hospital ethics committee.
Biochemical analysis
The blood sample after 12 hours fasting was collected in
tube for measuring. TG, total cholesterol (TC), HDLC and
LDLC were measured using the enzymatic method, and
APOA1 and APOB were determined by immunonephelo-
metry, and they all measured by automatic biochemistry
analyzer (Abbott Aeroset 2000, USA). APOC3 was also
measured by automatic biochemistry analyzer (Hitachi
7020, Japan). Samples for APOC3 were measured by a tur-
bidimetric immunoassay, and the reagents were obtained
from Sekisui medical co.(Japan) with a precipitant reagent
[phosphotungstic acid 0.55 mmol/l and magnesium chlor-
ide (MgCl2) 25 mmol]. HDL-APOC3 was assayed similarly
in the supernatant. TRL-APOC3 was calculated by sub-
stracting HDL-APOC3 from total APOC3.
Mutation analysis
TaqMan SNP Genotyping Assays were carried out to
detect the genotypes of APOC3 gene, including the T-
455C and C-482T, in 286 subjects with CHD and 325
controls. There was 20 missing data of genotype due to
the template reason(17 in CHD, and 3 in controls). A 2
ml whole-blood sample containing EDTA was collected
for each subject. Genomic DNA was extracted using a
Genomic DNA Kit(Axygen Biotechnology, shanghai,
China) according to the manufacturer’sp r o t o c o la n d
store the DNA samples in a -20°C freezer until use. Two
valid SNPs rs2854116(T-455C) and rs2854117(C-482T)
in the APOC3 gene that are found to be associated with
HTG were genotyped. Genotyping was performed apply-
ing a TaqMan assay that incorporates minor groove-
binding probe technology. A fluorogenic probe consisting
of an oligonucleotide labeled with both fluorescent repor-
ter and quencher dyes was included. The primers of
rs2854116 are AGAGCTCAGCCCTGTAACCA(forward)
and GGGCTTCTTCAGACTTGAGAACAA(reverse),
and the probes were VIC-ACTCCAAACATCCCCC-
MGB and FAM-CTCCAAACACCCCCC-MGB. The pri-
mers of rs2854117 were same as rs2854116, but the
probes were VIC-CAGAAGACCGGGCATC-MGB and
FAM-CAGAAGACCAGGCATC-MGB. All PCR reac-
tions were initially run in a final volume of 5 μl, compris-
ing of 2.5 μl TaqMan genotyping master mix, 0.25 μl
TaqMan SNP genotyping assay mix (40×), 1 μlD N A
samples, 1.25 μl water. All PCR reactions was carried out
in the ABI 7900 with 384 wells, consisting of an initial
step of 95°C for 5 min, followed by 40 cycles: denatura-
tion at 95°C for 15 sec, annealing at 60°C for 60 sec.
Amplicon size was 115 bp. Genotyping or allele calling
was carried out with the ABI Prism 7900HT genetic
detection system: SDS 2.3 software. A graph on the com-
puter would show the results of the allelic discrimination
plot by automatic allele calling. The horizontal axis indi-
cated an wild allele XX homozygote, the vertical axis
indicated mutant allele YY homozygote, and the diagonal
was allele X/Y heterozygote(Figure 1). When automatic
genotyping was not well done, re-testing, or direct
sequencing, until got the results. To validate the SNP
genotyping assays, 5% of the genotyped samples were
randomly selected for duplication accuracy with a direct
sequencing protocol(Sangon Biotech, Shanghai, China)
and all of the data for the TaqMan SNP Genotyping
Assays and direct sequencing analyses showed perfect
concordance.
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Baseline characteristics were shown as mean ± SD. Due to
plasma Lipid concentrations had a skewed distribution, the
median and interquartile ranges (Q:difference of Q25 and
Q75) were presented: M ± Q. The association between
genetic polymorphisms and the prevalence of CHD was
assessed using chi-square tests. Odds ratio was determined
by comparing each polymorphism (heterozygous, homozy-
gous) to wild type and the 95% confidence intervals were
calculated. Observed frequencies in the CHD and controls
were compared to the expected frequencies (Hardy-Wein-
berg equilibrium) by chi-square test. The distribution of
genotype and allele frequencies in CHD and controls were
analyzed by chi-square test too. The difference of lipid
levels in different genotypes in CHD and controls was eval-
uated by one-way ANOVA after rank transformation when
necessary. Linkage disequilibrium was calculated by Arle-
quin population genetics analysis software showed in value
of D’. All computations were performed by using the stata
8.0 or SAS 9.13 statistical software. Levels of significance
were defined as P <0 . 0 5 .
Results
Genotype and allele frequencies of the APOC3 poly-
morphic variants for CHD and controls were described
in Table 1. The allele frequencies of the rs2854117
(-482T) and rs2854116 (-455C) APOC3 alleles were
0.424 and 0.420 in CHD, 0.407 and 0.410 in controls,
respectively. Three polymorphisms were in the Hardy-
Weinberg equilibrium in relevant groups (data not
shown). There was no significant difference of the geno-
type and allele distribution between CHD and controls
(P > 0.05).
For the purpose of estimating the impact of the poly-
morphisms on APOC3 and lipid levels and other
accompany complications, genotype-phenotype analysis
was performed with data from the CHD and controls.
Compared to the wide type -455TT or -482CC, none of
the lipid variables and incidence of other accompany com-
plications analyzed showed any statistically relevant differ-
ences according to the variant APOC3 promoters in the
study population(Table 2).
To estimate the CHD risk associated with APOC3 geno-
types, logistic regression analysis was performed. Crude
and adjusted odds ratios for CHD related to APOC3 -455
and 482 genotypes are shown in Table 3. The polymorph-
isms of APOC3 gene promoter were not associated with a
significantly increased risk of CHD in the study population.
To estimate the CHD risk associated with APOC3 hap-
lotypes, Arlequin population genetics analysis software
Figure 1 TaqMan SNP Genotyping figure of indicated promoter polymorphisms in APOC3 gene. Left: T-455C, right: C-482T.
Table 1 Distribution of genotype and allele frequencies






-455CC 47(17.54) 54(16.72) 0.11 0.95
-455 Allele frequency
-455T 311(58.00) 381(59.00)




-482TT 48(17.91) 52(16.10) 0.38 0.83
-482 Allele frequency
-482C 309(57.60) 383(59.30)
-482T 227(42.40) 263(40.70) 0.32 0.57
Numbers in parentheses indicate each frequency of genotype or allele.
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haplotypes of APOC3 -455 and -482 and CHD in the
study population, but there was a strong linkage disequi-
librium between T-455C and C-482T with D’ = 0.9293,
0.8881, respectively(Table 5).
Discussion
APOC3, a 79 amino acid glycoprotein synthesized mainly
in the liver and to a lesser degree in the intestine, which
acted as a constituent of TRL particles and functioned as
a key regulator of serum triglyceride levels, inhibiting the
lipoprotein lipase-induced hydrolysis of those particles
and interfering with liver receptor-mediated lipoprotein
uptake. It played a key role in determining the levels in
the circulation of potentially atherogenic VLDL and
small dense LDL [15]. The results of large clinical studies
have indicated that sera APOC3 concentrations were a
better predictor of risk for the development and progres-
sion of CHD than the traditionally measured TG levels
[1,8]. APOC3 could also irritate several processes
involved in atherogenesis and vascular inflammation.
APOC3 stimulated blood-born monocytes and endothe-
lial cells to activate protein kinase C (PKC) and nuclear
factor B( N F - B) and expression of endothelialproduce
vascular cell adhesion molecule-1 (VCAM-1) and intra-
cellular adhesion molecule-1(ICAM-1), and recruitment
of monocytes to the vascular wall [16-18]. APOC3 could
also activate insulin-resistance pathways in endothelial
cells causing endothelial dysfunction [19] and stimulate
adipocytes to produce cytokines such as monocyte che-
moattractant protein (MCP) 1 and interleukin (IL)6 and
suppresses their production of adiponectin [20].
APOC3 was the first lipid-associated gene to be linked
by a common polymorphism to hypertriglyceridemia
Table 2 Biochemical parameter levels in study population, according to the APOC3 T-455C and C-482T genotypes
Parameters -455 Genotypes -482 Genotypes
-455TT -455TC -455CC -482 CC -482CT -482TT
Age (years) 55.64 ± 16.76 55.54 ± 16.21 55.48 ± 14.84 55.22 ± 16.60 55.56 ± 16.03 55.39 ± 15.11
Male sex (%) 65.7 62.5 60.4 66.5 61.0 63.0
TC (mmol/L) 3.92 ± 1.16 4.00 ± 1.18 3.84 ± 1.28 3.91 ± 1.18 3.99 ± 1.15 3.87 ± 1.33
TG (mmol/L) 1.29 ± 1.05 1.35 ± 1.17 1.50 ± 1.20 1.25 ± 0.98 1.38 ± 1.25 1.47 ± 1.12
HDLC (mmol/L) 1.12 ± 0.35 1.14 ± 0.38 1.10 ± 0.28 1.13 ± 037 1.13 ± 0.39 1.09 ± 0.27
LDLC (mmol/L) 2.34 ± 0.94 2.47 ± 0.80 2.40 ± 0.83 2.34 ± 0.90 2.44 ± 0.84 2.48 ± 0.85
APOAl (g/l) 1.3 ± 0.57 1.36 ± 0.58 1.29 ± 0.54 1.35 ± 0.57 1.33 ± 0.57 1.28 ± 0.56
APOB (g/l) 0.84 ± 0.29 0.85 ± 0.31 0.86 ± 0.31 0.84 ± 0.27 0.85 ± 0.31 0.88 ± 0.35
APOAl/APOB 1.69 ± 0.43 1.83 ± 0.60 1.68 ± 0.44 1.69 ± 0.40 1.84 ± 0.63 1.68 ± 0.42
APOC3(mg/dl) 8.10 ± 4.1 8.4 ± 4.5 7.95 ± 3.3 8.4 ± 4.3 8.1 ± 4.5 8.3 ± 3.1
HDL-APOC3
(mg/dl)
5.2 ± 2.4 5.4 ± 2.2 5.4 ± 1.8 5.2 ± 2.2 5.4 ± 2.2 5.4 ± 2.0
TRL-APOC3
(mg/dl)
3.35 ± 3.25 2.8 ± 2.6 3.5 ± 3.4 3.2 ± 3.1 3.0 ± 2.8 3.35 ± 3.15
T2DM (%) 20.1 20.56 26.73 18.2 21.1 28.0
Hypertension (%) 44.6 44.9 51.5 41.9 45.7 54.0
smoker(%) 44.9 45.5 38.4 44.7 43.5 43.2
drinker(%) 28.3 21.2 26.0 28.0 20.7 28.4
Data were shown as mean ± SD or %; skewed variables were M ± Q. M: median, Q: inter-quartile range, difference of Q25 and Q75.
Table 3 Odds Ratios for CHD according to APOC3 genotypes in the study population
Unadjusted Model adjusted Model
APOC3 genotypes Odds Ratio P value Odds Ratio P value
(95%CI) (95%CI)
-455TT 1 1
-455TC (-455TT as reference) 1.00 (0.66-1.51) 0.98 1.6 (0.20-6.81) 0.16
-455CC (-455TT as reference) 1.06(0.61-1.88) 0.82 5.67 (0.27-18.74) 0.26
-482CC 1 1
-482CT (-482CC as reference) 1.00 (0.66-1.51) 1.00 0.87 (0.12-6.25) 0.89
-482TT (-482CC as reference) 1.06 (0.60-1.87) 0.85 0.75 (0.20-2.73) 0.55
By multiple logistic regression analysis, The multiple logistic-regression model was adjusted for age, gender, presence of hypertension, T2DM, drinking, smoking
and all listed lipid leveles. CI, confidence interval. P values were for the overall comparison among subjects with a given polymorphism and were calculated by
chi-square analysis.
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the promoter region, was associated with an increased
risk of HTG [5], metabolic syndrome(MS)[22-24] and
CHD [12] in some race population. Association between
promoter SNPs of APOC3 and plasma triglyceride levels
have been consistently reported. The relationship with
CHD, however, was more controversial, with some stu-
dies indicating a possible link with genetic variability at
the locus [12] and others not confirming those associa-
tions [13]. In the present study, the association between
APOC3 SNPs and CHD was assessed by comparing the
SNPs distribution in CHD and controls without CHD.
We demonstrated the relationship between the two poly-
morphisms T-455C and C-482T and CHD in a randomly
selected population sample of Han Population in East
China. However, neither APOC3 T-455C nor C-482T
SNPs were clearly associated with CHD. Together with
previous reports, these results indicated that, although
APOC3 T-455C or C-482T variant has a vital impact on
plasma triglyceride concentration, this effect did not
increase significantly CHD risk.
Further haplotype analyses also did not found any signif-
icant frequency difference between CHD and controls, but
found there was a strong linkage disequilibrium between
T-455C and C-482T.
Ruiz et al reported that cardioprotective effects of pro-
moter common allele -455T or -482C of APOC3 gene
became dysfunctional in abdominal obesity and hypergly-
cemia in nonfatal MI [25]. Their research suggested that
the effect of the APOC3 -455C and -482T haplotype on
the risk of nonfatal MI was only evident in lean normogly-
cemic subjects. In the previous study we also found that
the effect of these two variant APOC3 genotype on the risk
of HTG was only evident in subjects in healthy population
and not in T2DM and speculated that probably because of
the existence of a strong insulin resistance in them masked
the effects of genetic polymorphism [7]. Indeed, recent stu-
dies have shown that patients homozygous for the -455C
APOC3 variant were poorly responsive to the APOC3-low-
ering effects of n-3 PUFAs [26]. CHD patients also suffered
from different complications, such as T2DM, Hyperten-
sion, abdominal obesity, and Fatty liver et al, they all could
mask the effect of a common APOC3 genotype on the risk
of CHD. Although we excluded the population of T2DM,
there was still no relationship found between them(data
not shown). Maybe there was other larval factors we yet
not found in CHD mask the association between APOC3
T-455C or C-482T and CHD. Such findings still have
other explanations. Firstly, the number of our study sam-
ples may be too low to detect a significant association. Sec-
ondly, CHD was a multifactorial desease, one or more
genetic variations combining with environmental factors
may result in phenotypic variability. Thirdly, part of CHD
risk attributable to elevated triglyceride levels was due to
structural alterations of LDL and HDL, such as oxidation.
Fourthly, race differences, genetic background, or environ-
mental differences or methodological flaws or nonrando-
mized selection of subjects. Finally, a number of conditions
such as age, obesity, gender, hormonal status may influence
the relationship between APOC3 gene polymorphisms and
CHD.
Conclusions
Altogether with previous and present findings suggested,
although APOC3 promoter variants had a key impact on
plasma triglyceride and APOC3 levels, this effect didn’t
raise significantly CHD risk in Chinese Han Population.
That was, APOC3 T-455C and C-482T SNPs were not
major risk factors of CHD in Han Population in East
China. However, other studies were necessary to confirm
these results and search for the causing facts.
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